Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical ...
ROCKVILLE, Md., June 06, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Phase I and/or Phase II …